Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
FLT1 2321 CEDIRANIB CHEMBL491473 inhibitor TALC, TdgClinicalTrial, ClearityFoundationClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions
FLT1 2321 Fruquintinib CHEMBL3545339 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions
FLT1 2321 SU-14813 CHEMBL3545160 inhibitor GuideToPharmacologyInteractions, ChemblInteractions
FLT1 2321 SUNITINIB CHEMBL535 inhibitor TALC, TdgClinicalTrial, CGI, TEND, DrugBank, MyCancerGenomeClinicalTrial 14654525, 17367763, 24086736, 21478036
FLT1 2321 CHEMBL101683 CHEMBL101683 DrugBank 10592235
FLT1 2321 REGORAFENIB CHEMBL1946170 inhibitor TALC, MyCancerGenome, ChemblInteractions, DrugBank, MyCancerGenomeClinicalTrial
FLT1 2321 ENMD-2076 CHEMBL482968 inhibitor MyCancerGenome, ClearityFoundationClinicalTrial
FLT1 2321 XL-820 CHEMBL3545402 inhibitor TdgClinicalTrial, ChemblInteractions
FLT1 2321 TABERMINOGENE VADENOVEC CHEMBL2108065 TdgClinicalTrial
FLT1 2321 TELBERMIN CHEMBL2108557 agonist, activator ChemblInteractions, TTD
FLT1 2321 L-21649 CHEMBL3544927 inhibitor ChemblInteractions
FLT1 2321 NINTEDANIB ESYLATE CHEMBL3039504 inhibitor ChemblInteractions
FLT1 2321 PAZOPANIB HYDROCHLORIDE CHEMBL1201733 inhibitor ChemblInteractions
FLT1 2321 Sulfatinib CHEMBL3545251 inhibitor ChemblInteractions
FLT1 2321 BRIVANIB CHEMBL377300 inhibitor GuideToPharmacologyInteractions, ChemblInteractions
FLT1 2321 CEP-11981 CHEMBL2010872 inhibitor GuideToPharmacologyInteractions, ChemblInteractions
FLT1 2321 DOVITINIB CHEMBL522892 inhibitor TdgClinicalTrial, ClearityFoundationClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, CancerCommons
FLT1 2321 FORETINIB CHEMBL1230609 inhibitor MyCancerGenome, GuideToPharmacologyInteractions, ChemblInteractions
FLT1 2321 LINIFANIB CHEMBL223360 inhibitor MyCancerGenome, TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, DrugBank
FLT1 2321 MK-2461 CHEMBL1822792 inhibitor GuideToPharmacologyInteractions
FLT1 2321 SEMAXANIB CHEMBL276711 inhibitor GuideToPharmacologyInteractions, ChemblInteractions
FLT1 2321 TG100-801 CHEMBL403989 inhibitor ChemblInteractions, DrugBank
FLT1 2321 CHEMBL313417 CHEMBL313417 TdgClinicalTrial
FLT1 2321 ORANTINIB CHEMBL274654 inhibitor MyCancerGenome
FLT1 2321 X-82 CHEMBL3545401 inhibitor MyCancerGenome, ChemblInteractions
FLT1 2321 TESEVATINIB CHEMBL3544983 inhibitor MyCancerGenome, TdgClinicalTrial
FLT1 2321 TERIPARATIDE CHEMBL525610 TTD
FLT1 2321 TELATINIB CHEMBL2079588 TdgClinicalTrial
FLT1 2321 XL-999 CHEMBL3545285 inhibitor TdgClinicalTrial, ChemblInteractions
FLT1 2321 LENVATINIB MESYLATE CHEMBL2105704 inhibitor ChemblInteractions
FLT1 2321 KRN-633 CHEMBL406381 inhibitor ChemblInteractions
FLT1 2321 BRIVANIB ALANINATE CHEMBL270995 inhibitor ChemblInteractions
FLT1 2321 CEP-7055 CHEMBL346631 inhibitor ChemblInteractions
FLT1 2321 TAK-593 CHEMBL2180604 inhibitor ChemblInteractions
FLT1 2321 Anlotinib CHEMBL3545021 inhibitor GuideToPharmacologyInteractions
FLT1 2321 DORSOMORPHIN CHEMBL478629 inhibitor GuideToPharmacologyInteractions
FLT1 2321 LUCITANIB CHEMBL2220486 inhibitor GuideToPharmacologyInteractions, ChemblInteractions, MyCancerGenomeClinicalTrial
FLT1 2321 MOTESANIB CHEMBL572881 inhibitor TALC, MyCancerGenome, TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions
FLT1 2321 OSI-930 CHEMBL1614710 inhibitor GuideToPharmacologyInteractions, ChemblInteractions, DrugBank
FLT1 2321 PAZOPANIB CHEMBL477772 inhibitor TALC, MyCancerGenome, TdgClinicalTrial, GuideToPharmacologyInteractions, DrugBank, MyCancerGenomeClinicalTrial 17288876
FLT1 2321 TIVOZANIB CHEMBL1289494 inhibitor TALC, MyCancerGenome, TdgClinicalTrial, ClearityFoundationClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, CancerCommons
FLT1 2321 VATALANIB CHEMBL101253 inhibitor TALC, MyCancerGenome, TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, DrugBank 17584317
FLT1 2321 MGCD-265 CHEMBL254760 inhibitor TALC, MyCancerGenome, TdgClinicalTrial, ChemblInteractions
FLT1 2321 VANDETANIB CHEMBL24828 inhibitor TdgClinicalTrial, ClearityFoundationClinicalTrial, ChemblInteractions, MyCancerGenomeClinicalTrial
FLT1 2321 SORAFENIB TOSYLATE CHEMBL1200485 inhibitor ChemblInteractions, MyCancerGenomeClinicalTrial
FLT1 2321 ILORASERTIB CHEMBL1980297 inhibitor ChemblInteractions
FLT1 2321 CEP-5214 CHEMBL150894 inhibitor ChemblInteractions
FLT1 2321 RG-1530 CHEMBL1980391 inhibitor ChemblInteractions
FLT1 2321 BMS-690514 CHEMBL3545396 inhibitor ChemblInteractions
FLT1 2321 Famitinib CHEMBL3545026 inhibitor ChemblInteractions
FLT1 2321 ICRUCUMAB CHEMBL1743030 antagonist ChemblInteractions
FLT1 2321 4SC-203 CHEMBL3545358 inhibitor ChemblInteractions
FLT1 2321 SORAFENIB CHEMBL1336 inhibitor MyCancerGenome, DrugBank, MyCancerGenomeClinicalTrial, TTD 17016424, 15466206, 16507829
FLT1 2321 CHEMBL261720 CHEMBL261720 inhibitor GuideToPharmacologyInteractions
FLT1 2321 NINTEDANIB CHEMBL502835 inhibitor, Inhibitor TALC, MyCancerGenome, TdgClinicalTrial, ClearityFoundationClinicalTrial, GuideToPharmacologyInteractions, DrugBank 18559524
FLT1 2321 PLX-3397 CHEMBL3545158 inhibitor GuideToPharmacologyInteractions
FLT1 2321 IMC-1C11 CHEMBL2109257 DrugBank
FLT1 2321 AXITINIB CHEMBL1289926 inhibitor MyCancerGenome, CancerCommons, MyCancerGenomeClinicalTrial, ChemblInteractions, DrugBank, TALC, TdgClinicalTrial, PharmGKB 18541897
FLT1 2321 PEGPLERANIB SODIUM CHEMBL3301576 TdgClinicalTrial
FLT1 2321 LENVATINIB CHEMBL1289601 inhibitor TALC, TdgClinicalTrial
FLT1 2321 RANIBIZUMAB CHEMBL1201825 inhibitor TTD
FLT1 2321 Chiauranib CHEMBL3545428 inhibitor ChemblInteractions
FLT1 2321 AEE-788 CHEMBL587723 inhibitor ChemblInteractions
FLT1 2321 AG-13958 CHEMBL3545335 inhibitor ChemblInteractions
FLT1 2321 SUNITINIB MALATE CHEMBL1567 inhibitor ChemblInteractions
FLT1 2321 CP-459632 CHEMBL3545300 inhibitor ChemblInteractions
FLT1 2321 SU-014813 CHEMBL1721885 inhibitor ChemblInteractions

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
FLT1 rs664393 CT + TT cisplatin efficacy no No significant association was found in progression free survival or overall survival. Genotypes CT + TT are not associated with response to cisplatin, fluorouracil and oxaliplatin in people with Stomach Neoplasms as compared to genotype CC. 24090479 1183700989
FLT1 rs7993418 AG + GG cisplatin efficacy no No significant association was found in progression free survival or overall survival. Genotypes AG + GG are not associated with response to cisplatin, fluorouracil and oxaliplatin in people with Stomach Neoplasms as compared to genotype AA. 24090479 1183700993
FLT1 rs12877323 G bevacizumab efficacy no Neovascular age-related macular degeneration. Response was based on the optical coherence tomography (OCT) metric of total retinal thickness (TRT). Change in TRT was calculated between baseline and after 3, 6, 9 or 12 months of treatment, depending on the patient. Eyes with TRT changes >= the 75th percentile were classified as responders; those with changes <= the 25th percentile were classified as nonresponders. Cases = responders; controls = nonresponders. p-value was Bonferroni-corrected for 482 tests (uncorrected p-value = 0.004). Allele G is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to allele T. 24070809 1184165258
FLT1 rs7995976 A anthracyclines and related substances efficacy no Patients were women with HER2- breast cancer. SNPs in genes in the VEGF pathway were selected to be genotyped (170 plus 16 that were previously investigated for association with response to bevacizumab) and compared between women who received bevacizumab and women who did not. The response was "pathological complete response". This SNP was one of the top 10 SNPs to show association with response to bevacizumab, but did not remain associated after multiple testing correction. Allele A is not associated with response to anthracyclines and related substances, bevacizumab, cyclophosphamide, docetaxel, epirubicin and taxanes in women with Breast Neoplasms as compared to allele C. 26100253 1447813768
FLT1 rs7993418 G imatinib dosage no No significant association between genotype and chance of requiring an imatinib dose reduction. Allele G is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele A. 30713339 1450933601